Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Bendamustine
Related studies linked through entity extraction aliases.
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
- Status
- RECRUITING
- Phase
- PHASE3
Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
- Status
- RECRUITING
- Phase
- PHASE3
Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Status
- RECRUITING
- Phase
- PHASE3
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Status
- RECRUITING
- Phase
- PHASE3
BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
- Status
- RECRUITING
- Phase
- PHASE2
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
- Status
- RECRUITING
- Phase
- PHASE3
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
- Status
- RECRUITING
- Phase
- PHASE3
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3